Company Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells.
The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders.
The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania.
The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011.
The company was incorporated in 1997 and is based in Melville, New York.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Lance Alstodt |
Contact Details
Address: 40 Marcus Drive Melville, New York 11747 United States | |
| Phone | (631) 760-8100 |
| Website | biorestorative.com |
Stock Details
| Ticker Symbol | BRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505497 |
| CUSIP Number | 090655606 |
| ISIN Number | US0906556065 |
| Employer ID | 30-1341024 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Lance Alstodt | Chairman of the Board, President and Chief Executive Officer |
| Robert Eugene Kristal | Chief Financial Officer |
| Francisco J. Silva | Chief Scientist, Vice President of Research and Development, Secretary and Director |
| Robert Paccasassi | Vice President of Quality Assurance and Regulatory Compliance |
| Dr. Wayne J. Olan M.D. | Clinical Director of Regenerative Disc and Spine Program and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 424B3 | Prospectus |
| Apr 18, 2024 | EFFECT | Notice of Effectiveness |
| Apr 12, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 3, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |